Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa booster immunogenicity in infants of mothers vaccinated with Boostrix during pregnancy or after delivery
2014-001120-30Phase 4Completed
- Sponsor
- GSK
- Start
- May 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertussis filamentous haemagglutinin and acellular pertussis vaccine in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by GSK. Primary endpoint: Seroprotection one month after booster dose. Started May 2016; status: completed.
02
Drugs
pertussis filamentous haemagglutininacellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2014-001120-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001120-30.